SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

AdTab

ELAN·Elanco Animal Health Inc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved/Marketed
Time to market
Already launched and marketed in Europe (Spain, Portugal, Austria) since 2023-2024.
Why 3/10
AdTab is an already-approved, marketed product (launched in Spain and Portugal in 2023, available in Austria by 2024) with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. It is a small regional brand within Elanco's much larger Credelio lotilaner franchise, so no hard dated binary catalyst exists.
Actionable Insight NEUTRAL

AdTab is a minor regional brand extension of Elanco's lotilaner (Credelio) franchise, launched in select European markets. It faces heavy competition from established flea/tick brands (Bravecto, NexGard, Simparica) and Elanco's own Credelio line. No upcoming binary catalysts exist for this specific product; watch Elanco's broader pet health portfolio (Credelio Quattro, Zenrelia) for material drivers.

Price Chart

Loading chart...

Executive Summary

AdTab is Elanco's brand name for lotilaner flea and tick chewable tablets sold in select European markets (Spain, Portugal, Austria). It contains the same active ingredient as Elanco's larger US Credelio franchise. Launched in Spain and Portugal in July 2023, AdTab is a commercially available, approved product with no pending regulatory catalysts. It is a very small part of Elanco's diversified animal health business, which generated $1.265 billion in Q3 2026 revenue. The stock trades at around $25.80 with a consensus analyst price target of $30.69 (19% implied upside) and 19 of 22 analysts rating it Buy or Strong Buy.

How It Works

AdTab is a chewable tablet for dogs and cats that kills fleas and ticks. Its active ingredient, lotilaner, targets the nervous system of insects and arachnids (but not mammals), causing rapid paralysis and death of the parasites. It is given monthly with food.

Trial Status

AdTab is a commercially available product, not in clinical trials. It contains lotilaner, the same active ingredient as Elanco's Credelio line, which has FDA approval in the US and regulatory approvals in Europe.

The Two-Sided Case

▲ Bull Case4
Lotilaner is a proven, effective active ingredient with FDA approval in the US under the Credelio brand and a strong safety profile.
Elanco's broader pet health portfolio is growing: Q3 2026 revenue rose 11% YoY to $1.265B, and the company raised its full-year 2026 outlook.
Analyst consensus is bullish: 19 of 22 analysts rate ELAN Buy or Strong Buy, with a mean price target of $30.69 (19% upside from $25.74).
Institutional interest is strong: Citadel doubled its position, and multiple funds initiated new positions in Q2 2026.
▼ Bear Case4
AdTab is a minor regional brand confined to a few European markets, competing against well-established flea/tick brands like Bravecto (Merck), NexGard (Boehringer), and Simparica (Zoetis), as well as Elanco's own Credelio.
Elanco faces a consumer price-fixing class action lawsuit over its flea and tick product market practices, which introduces legal overhang.
Elanco carries significant debt; the company sold $295M in future lotilaner royalty rights in 2025 to accelerate debt repayment, signaling cash needs.
The product has no upcoming binary catalysts, making it a non-event for the stock on its own.

Upcoming Catalysts

  • No upcoming catalysts specific to AdTab. For Elanco broadly, watch Q4 2026 earnings and continued adoption of Credelio Quattro and Zenrelia.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Elanco Animal Health Inc 8-K ELAN ·Originating report

Sources · 8

Hover a chip for the title
1 interempresas.net2 krone.at3 krone.at4 msn.com5 ad-hoc-news.de6 reuters.com7 ibj.com8 webmd.com